PDSB: רווח נקי למניה (EPS TTM) PDS Biotechnology Corp

PDS Biotechnology faces a dependency on the Versamune test results and external financing. The TTM net income per share distribution reflects earnings dynamics, with the parameter stabilizing at -0.63. The company's innovative ecosystem integrates vaccines and immunotherapy to combat metastases. The stability of the R&D core is ensured by an effective incentive system for leading oncologists and researchers.

Net income per share (TTM) measures the actual business profitability distributed per share over a trailing twelve-month period. By analyzing the annual net income per share trend via GURU.Markets, an investor can observe the current balance of supply and demand. This metric is calculated by dividing the total annual income by the total number of shares outstanding. For PDS Biotechnology (PDSB), this indicator is critical during the implementation of robotic biomolecule screening. The automation of oncology drug development should optimize costs, directly impacting the future dynamics of this fundamental value.